Clinical Trial Search

Primary: Response Rate — 0; 5 percentage of responding patients

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST — 0 patients

Primary: Median Overall Survival — 31.1 months

Primary: Local Tumor Recurrence Rate — 4; 0 Participants

Primary: Response Rate — 2; 13; 21; 1 Participants

Primary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale

Primary: Progression-free Survival (PFS) — 23.1 percentage of participants

Primary: Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST) — 3 percentage of participants

Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients

Primary: Dose-limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of Belinostat in Patients With Inoperable HCC (Phase I) — 0; 0; 0; 1 Participants

Primary: Number of Subjects Experiencing Adverse Events — 2 participants

Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants

Primary: Progression-Free Survival — 51 percentage of participants

Primary: Time to Progression — 2.3; 7.2 Months

Primary: Progression-free Survival (PFS) — 37.0 percentage of participants

Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks

Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 0; 2 Participants

Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants

Primary: Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR). — 0; 1 participants

Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants

Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants

Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants

Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants

Primary: Response Rate by Recist Criteria — 6 participants

Primary: Tumor Response — 0; 7; 47; 11 Participants

Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…

Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants